Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Net Cash Flow (2017 - 2026)

Cogent Biosciences' Net Cash Flow history spans 10 years, with the latest figure at -$70.8 million for Q1 2026.

  • Quarterly Net Cash Flow fell 354.34% to -$70.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $115.6 million through Mar 2026, up 228.76% year-over-year, with the annual reading at $214.3 million for FY2025, 376.82% up from the prior year.
  • Net Cash Flow came in at -$70.8 million for Q1 2026, down from $186.8 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $186.8 million in Q4 2025 to a low of -$185.0 million in Q3 2022.
  • The 5-year median for Net Cash Flow is $1.1 million (2024), against an average of $1.2 million.
  • Year-over-year, Net Cash Flow crashed 4823.9% in 2023 and then skyrocketed 16578.12% in 2025.
  • Cogent Biosciences' Net Cash Flow stood at -$682000.0 in 2022, then plummeted by 4823.9% to -$33.6 million in 2023, then soared by 103.34% to $1.1 million in 2024, then surged by 16578.12% to $186.8 million in 2025, then crashed by 137.9% to -$70.8 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Net Cash Flow are -$70.8 million (Q1 2026), $186.8 million (Q4 2025), and -$2.0 million (Q3 2025).